Department of Surgery, Yokohama City University, Yokohama, Japan;
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Anticancer Res. 2023 Nov;43(11):5181-5187. doi: 10.21873/anticanres.16719.
BACKGROUND/AIM: The C-reactive protein to prealbumin ratio (CPAR) has been proposed and introduced in gastrointestinal cancer management. This study aimed to evaluate the clinical impact of the CPAR in patients with gastric cancer (GC) who received curative treatment.
This study included 447 patients who underwent curative treatment for GC between 2013 and 2017. The prognosis and clinicopathological parameters were compared between patients with high and low CPARs.
Overall survival (OS) stratified by each clinical factor was compared using the log-rank test, and a significant difference was observed using a pretreatment CPAR of 5.0. Significant differences were observed in the 3- and 5-year OS rates of the CPAR-low (CPAR <5.0) and CPAR-high (CPAR ≥5.0) groups. The 3- and 5-year OS rates were 92.6% and 87.8%, respectively, in the CPAR-low group and 88.0% and 75.4% in the CPAR-high group. The CPAR was determined to be a significant prognostic factor for OS in a multivariate analysis (p=0.032). Similar results were observed for recurrence-free survival.
The CAPR is a prognostic factor for GC patients. Therefore, the CAPR may be a promising nutritional biomarker of inflammation that can be applied in the management of GC patients.
背景/目的：C 反应蛋白与前白蛋白比值（CPAR）已被提出并应用于胃肠道癌症的治疗管理中。本研究旨在评估 CPAR 在接受根治性治疗的胃癌（GC）患者中的临床影响。
本研究纳入了 2013 年至 2017 年间接受根治性治疗的 447 例 GC 患者。比较了高、低 CPAR 患者的预后和临床病理参数。
使用对数秩检验对每个临床因素分层的总生存期（OS）进行比较，CPAR 术前为 5.0 时存在显著差异。CPAR 低（CPAR <5.0）和 CPAR 高（CPAR ≥5.0）组的 3 年和 5 年 OS 率存在显著差异。CPAR 低组的 3 年和 5 年 OS 率分别为 92.6%和 87.8%，CPAR 高组分别为 88.0%和 75.4%。CPAR 在多因素分析中被确定为 OS 的显著预后因素（p=0.032）。无复发生存率也存在类似结果。
CPAR 是 GC 患者的预后因素。因此，CPAR 可能是一种有前途的炎症营养生物标志物，可应用于 GC 患者的治疗管理中。
